Authorised psychiatrists can access products containing 3,4‑methylenedioxy‑methamphetamine (MDMA) or psilocybin for specific mental health conditions from 1 July 2023.
MDMA can be used for the treatment of post-traumatic stress disorder.
Psilocybin can be used for treatment-resistant depression.
To access products containing MDMA or psilocybin, you must be a registered psychiatrist approved under the TGA's Authorised Prescriber scheme.
- Access MDMA or psilocybin (consumers)PageMDMA can be accessed to treat post-traumatic stress disorder (PTSD). Psilocybin can be accessed for treatment-resistant depression (TRD).
- Prescribe MDMA or psilocybin (psychiatrists)PageClinical resources and guidance on accessing MDMA and psilocybin under the Authorised Prescriber scheme.
- Dispense or compound MDMA and psilocybin (pharmacists)PageInformation for pharmacists on dispensing, supplying and compounding MDMA and psilocybin.
- Supply, manufacture or import MDMA or psilocybin (sponsors and manufacturers)PageInformation for Australian sponsors on manufacturing, supplying and importing MDMA and psilocybin.
Topics